Join the Oncology Brothers, in this insightful episode as they dive deep into the treatment algorithms for newly diagnosed multiple myeloma and smoldering myeloma. Featuring Gurbakhash Kaur, MD, a myeloma specialist from the Mount Sinai Hospital, the discussion covered the latest advancements in treatment options, including the recent approval of daratumumab for high-risk smoldering myeloma and the evolving landscape of frontline therapies.

In this episode, you'll learn about:

Listen us on:

Follow us on social media:

Whether you're a healthcare professional or someone interested in the latest in oncology, this episode provides valuable insights into the complexities of treating multiple myeloma. Don't miss out on this informative discussion!

#MultipleMyeloma, #SmolderingMyeloma, #HemeMalignancy, #MRD, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the latest highlights from the EHA 2026 conference, focusing on groundbreaking studies in the leukemia space.

Join us as we welcome Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center to discuss three pivotal studies:

Listen us on:

Follow us on social media:

Tune in for an insightful discussion on the future of leukemia treatment and the importance of genetic markers in therapy decisions. Don't forget to like, subscribe, and check out our other conference highlights from ASCO and EHA!

#EHA2026, #Leukemia, #AML, #Myelofibrosis, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely?

Key topics discussed included:

Listen us on:

Follow us on social media:

Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!

#DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.

Join us as we dived into four pivotal studies:

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Tune in for an insightful discussion on these important studies and their potential impact on clinical practice.

Don't forget to subscribe for more updates on conference highlights, FDA approvals, and treatment algorithms!

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approvals for sacituzumab govitecan in frontline settings for metastatic triple-negative breast cancer. Joined by Dr. Sara Tolaney, a breast medical oncologist from the Dana-Farber Cancer Institute, we discussed the exciting developments in breast cancer treatment, with ASCENT-03 and ASCENT-04 trials.

Key topics covered in this episode include:

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

Join us as we explored the evolving landscape of breast cancer treatment and the importance of shared decision-making in patient care. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#TripleNegativeBreastCancer, #Sacituzumab, #ASCENT03, #ASCENT04, #OncologyBrothers

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.

Key topics included:

Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life.

Listen us on:

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!

#Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma

In this ASCO 2026 Highlights discussion we dived into the latest advancements in breast cancer space. In this episode, we welcomed back Dr. Hope Rugo to discuss key studies that are shaping the future of breast cancer treatment.

Episode Highlights:

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Hope this episode provided the very needed updates from ASCO 2026 focusing on the breast cancer world. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#BreastCancer #ASCO2026 #ClinicalTrials #PrecisionOncology #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.

Join us as we dived into:

We emphasized the importance of managing side effects and optimizing treatment sequences to ensure our patients can stay on these innovative therapies longer and safely.

Tune in for an informative discussion packed with the latest research and clinical insights in the world of oncology!

Listen to us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.

Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.

Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.

Topics Covered:

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  

Follow us on social media:

Tune in now and stay informed about the latest in oncology!

#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.

We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.

Key topics covered in this episode included:

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms!

#KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI, #OncologyBrothers